切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2018, Vol. 07 ›› Issue (02) : 120 -124. doi: 10.3877/cma.j.issn.2095-3224.2018.02.004

所属专题: 文献

青年专家论坛

2017年ESMO结直肠癌领域研究进展解读——基础应用篇
隋红1,()   
  1. 1. 150040 哈尔滨医科大学附属肿瘤医院内二科
  • 收稿日期:2017-09-17 出版日期:2018-04-25
  • 通信作者: 隋红
  • 基金资助:
    国家自然科学基金青年基金资助项目(No.81201876); 黑龙江省青年自然基金项目(No.QC2012C011); 黑龙江省博士后基金项目(No.LBH-Z12210); 吴阶平医学基金会临床基金项目(No.320.6750.15255)

Highlights in the field of colorectal cancer comes from 2017 ESMO congress——basic application

Hong Sui1,()   

  1. 1. Medical Department, Harbin Medical University Cancer Hospital, Harbin 150040, China
  • Received:2017-09-17 Published:2018-04-25
  • Corresponding author: Hong Sui
  • About author:
    Corresponding author: Sui Hong, Email:
引用本文:

隋红. 2017年ESMO结直肠癌领域研究进展解读——基础应用篇[J]. 中华结直肠疾病电子杂志, 2018, 07(02): 120-124.

Hong Sui. Highlights in the field of colorectal cancer comes from 2017 ESMO congress——basic application[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(02): 120-124.

European Society For Medical Oncology(ESMO)大会是欧洲最具影响力的肿瘤专家年度会议。2017年ESMO大会于2017年9月8日至12日在西班牙马德里举行,大会将癌症研究人员和临床医生聚集在一起,开展合作,交流思想,促进实验室到临床以及从临床到实验室的相互转化。现将会议期间有关结直肠癌领域临床前沿及引申的基础研究诸如免疫治疗优化获益人群、转化研究、肿瘤标记物、肿瘤基因型和表型的变化与疾病预后以及治疗方式和/或药物选择的相关性、结直肠癌新靶点等做一简要梳理。

The European Society For Medical Oncology (ESMO) congress is the most influential annual meeting for oncology professionals in Europe. The 2017 ESMO Congress was held in Madrid, Spain from 8th to 12th September 2017 and brought cancer researchers and clinicians together to enable collaboration and exchange their ideas from the laboratory to the bedside and back. Here, development in basic research of colorectal cancer will be summarized including following points such as optimizing the beneficiaries for immunotherapy, translational research, tumor bio-marker, genotypic and phenotypic alteration in cancer related to disease prognosis, manipulation and/or drug choice, therapeutic target in mCRC treatment.

表1 肿瘤dMMR/MSI-H与mCRC患者应用NIVO单抗+IPI单抗临床疗效相关(CheckMate142研究结果汇报)
[1]
Andre T., Overman M., Lonardi S., et al. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) 1 ipilimumab (IPI): CheckMate 142[C]. ESMO, 2017, Abstract 484 PD.
[2]
Mooi J., Wirapati P., Asher R., et al. Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial[C]. ESMO, 2017, Abstract 479O.
[3]
Tsimberidou A.M., Sabanes Bove D., Bouseida S., et al. Early FDG-PET response correlates with dose and clinical efficacy in patients with microsatellite stable (MSS) metastatic CRC (mCRC) treated with the CEA-CD3 T-cell bispecific antibody plus atezolizumab[C]. ESMO, 2017, Abstract 367PD.
[4]
Gallois C., Taieb J., Le Corre D., et al. Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy[C]. ESMO, 2017, Abstract 480O.
[5]
Schwartz S., Cecchi F., Tian Y., et al. Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT[C]. ESMO, 2017, Abstract 145P.
[6]
Perez White BE, Ventrella R, Kaplan N, et al.EphA2 proteomics in human keratinocytes reveals a novel association with afadin and epidermal tight junctions[J].J Cell Sci, 2017, 130(1):111-118.
[7]
Martini G., Belli V., Vitiello P.P., et al.EPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC)[C]. ESMO, 2017, Abstract1636P.
[8]
Cardone C., Paul M.C., Moreno-Viedma V., et al. Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI+cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial[C]. ESMO, 2017, Abstract 1637P.
[9]
Mortazavizaden S.M.R., Ayoughi Y., Moghimi M., et al. The combination analysis of tumor infiltration lymphocyte with Neutrophil to lymphocyte ratio may predict prognosis of colorectal cancer in stage[C]. ESMO, 2017, Abstract1712P.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 李晨曦, 谭小容, 魏巍, 李慕秋, 龚忠诚. 三级淋巴结构在口腔癌中的特征及意义[J]. 中华口腔医学研究杂志(电子版), 2023, 17(05): 315-321.
[3] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[4] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[5] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[6] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[7] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[8] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[9] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[10] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[11] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[12] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[13] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[14] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要